期刊文献+

晚期卵巢癌术后紫杉醇联合顺铂进行静脉和腹腔双途径化疗效果观察 被引量:6

原文传递
导出
摘要 目的观察晚期卵巢癌术后采取紫杉醇联合顺铂进行静脉及腹腔双途径化疗的临床疗效。方法将204例晚期卵巢癌患者随机分为观察组及对照组各102例,观察组采用紫杉醇联合顺铂进行静脉及腹腔双途径化疗,对照组将2种药物静脉滴注,比较2组患者的临床疗效及不良反应的情况。结果观察组患者总有效率为96.1%高于对照组68.6%(P<0.05);观察组患者血小板减少、肝肾功能损害等不良反应发生率低于对照组(P<0.05),同时观察组恶心呕吐、白细胞减少、脱发、贫血等不良反应发生率低于对照组,但2组间差异无统计学意义(P>0.05)。结论紫杉醇联合顺铂进行静脉及腹腔双途径化疗治疗晚期卵巢癌的临床疗效更佳,不良反应发生率较低,具有重要临床意义。
出处 《临床合理用药杂志》 2015年第1期49-50,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献9

二级参考文献82

共引文献167

同被引文献44

  • 1舒进忠,谭诗生.紫杉醇联合顺铂腹腔灌注治疗晚期卵巢癌的临床疗效及其对免疫调节作用的研究[J].中国生化药物杂志,2014,34(2):130-132. 被引量:34
  • 2SIEGEL R, MA J,ZOU Z,et al. Cancer statistics, 2014 [J].CA Cancer J Clin, 2014,64(1) :9-29.
  • 3KIPPS E, TAN DS, KAYE SB. Meeting the challenge of ascitesin ovarian cancer: new avenues for therapy and research [J].Nat Kev Cancer, 2013,13(4):273-282.
  • 4QIAN X,QIN J, PAN S, et al. Maintenance therapy in ovariancancer with targeted agents improves PFS and OS : a systematicreview and meta-Analysis [J]. PLoS One, 2015,10 (9):e!39026.
  • 5FEIGENBERG T, CLARKE B, VIRTANEN C, et al. Molecularprofiling and clinical outcome of high-grade serous ovariancancer presenting with low-versus high-volume ascites [J].Biomed Res Int, 2014,2014(5):367103.
  • 6LANE D, MATTE I, GARDE-GRANGER P, etal. Inflammation-regulating factors in ascites as predictive biomarkers of drugresistance and progression-free survival in serous epithelialovarian cancers [J]. BMC Cancer, 2015,15(7) :492-503.
  • 7ELIT L, OLIVER TK, COVENS A, et al. Intraperitonealchemotherapy in the first-line treatment of women with stage IIIepithelial ovarian cancer : a systematic review with metaanalyses[J]. Cancer, 2007,109(4):692-702.
  • 8JAABACK K, JOHNSON N,LAWRIE TA. Intraperitonealchemotherapy for the initial management of primary epithelialovarian cancer [J]. Cochrane Database Syst Rev, 2011,11(11):CD005340.
  • 9MARKMAN M, BUNDY BN, ALBERTS DS, et al. Phase II1 trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose earboplatin followed by intravenous paclitaxel and intraperitoneal eisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oneology Group, Southwestern Oneology Group, and Eastern Cooperative Oneology Group [J]. J Clin Oneol, 2001,19(4) : 1001-1007.
  • 10ARMSTRONG DK, BUNDY B, WENZEL L, et al. Intraperitonealcisplatin and paclitaxel in ovarian cancer [J], N Engl J Med,2006,354(l):34-43.

引证文献6

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部